KR20090059126A - 암을 치료하기 위한 방법 및 조성물 - Google Patents

암을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20090059126A
KR20090059126A KR1020097005974A KR20097005974A KR20090059126A KR 20090059126 A KR20090059126 A KR 20090059126A KR 1020097005974 A KR1020097005974 A KR 1020097005974A KR 20097005974 A KR20097005974 A KR 20097005974A KR 20090059126 A KR20090059126 A KR 20090059126A
Authority
KR
South Korea
Prior art keywords
day
hydroxylase
effective amount
therapeutically effective
lyase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097005974A
Other languages
English (en)
Korean (ko)
Inventor
알란 에이치. 아우어바크
아리 에스. 벨데그룬
Original Assignee
코우가 바이오테크놀로지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090059126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 코우가 바이오테크놀로지, 인크. filed Critical 코우가 바이오테크놀로지, 인크.
Publication of KR20090059126A publication Critical patent/KR20090059126A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020097005974A 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물 Ceased KR20090059126A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
US60/921,506 2006-08-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157025243A Division KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20090059126A true KR20090059126A (ko) 2009-06-10

Family

ID=38916904

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020097005974A Ceased KR20090059126A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020157025243A Ceased KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020177037293A Ceased KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020207031218A Ceased KR20200125776A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020157025243A Ceased KR20150108946A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020177037293A Ceased KR20180003636A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물
KR1020207031218A Ceased KR20200125776A (ko) 2006-08-25 2007-08-23 암을 치료하기 위한 방법 및 조성물

Country Status (20)

Country Link
EP (3) EP3804730A1 (https=)
JP (10) JP2010501575A (https=)
KR (4) KR20090059126A (https=)
CN (2) CN104306977A (https=)
AU (6) AU2007287098C1 (https=)
CA (1) CA2661422C (https=)
CY (2) CY1115477T1 (https=)
DK (2) DK2061561T3 (https=)
ES (2) ES2869343T3 (https=)
HR (2) HRP20130961T1 (https=)
HU (1) HUE054495T2 (https=)
IL (3) IL197211A0 (https=)
LT (1) LT2478907T (https=)
NO (2) NO20091190L (https=)
NZ (1) NZ597830A (https=)
PL (2) PL2478907T3 (https=)
PT (2) PT2061561E (https=)
RS (2) RS52956B (https=)
SI (2) SI2061561T1 (https=)
WO (1) WO2008024484A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2478907T3 (pl) 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
PE20090931A1 (es) * 2007-10-29 2009-08-03 Takeda Pharmaceutical Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
SG10201600077RA (en) 2011-01-11 2016-02-26 Glaxosmithkline Llc Combination
WO2012135781A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
WO2014165779A1 (en) * 2013-04-04 2014-10-09 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
MX2016004265A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CN109806266A (zh) * 2013-10-01 2019-05-28 诺华股份有限公司 用于癌症治疗的组合及其应用
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
HUE060460T2 (hu) * 2017-04-13 2023-03-28 Janssen Pharmaceutica Nv Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
US10792292B2 (en) * 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN115427016A (zh) * 2020-04-16 2022-12-02 塔凡塔医疗匈牙利公司 用于治疗前列腺癌的方法和组合物
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
EP1276482B1 (en) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
SI1556058T1 (sl) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
PL2478907T3 (pl) 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu

Also Published As

Publication number Publication date
AU2007287098A1 (en) 2008-02-28
ES2428634T3 (es) 2013-11-08
DK2478907T3 (da) 2021-05-25
JP6445123B2 (ja) 2018-12-26
DK2061561T3 (da) 2013-10-07
CA2661422C (en) 2017-06-27
AU2017201764A1 (en) 2017-04-06
JP2012082215A (ja) 2012-04-26
EP3804730A1 (en) 2021-04-14
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
JP2020114851A (ja) 2020-07-30
HRP20130961T1 (hr) 2013-11-22
JP6053279B2 (ja) 2016-12-27
JP2024164147A (ja) 2024-11-26
SI2478907T1 (sl) 2021-08-31
CN104306977A (zh) 2015-01-28
AU2015221447A1 (en) 2015-09-17
AU2015221447B2 (en) 2016-12-15
IL227746A0 (en) 2013-09-30
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
AU2018271331A1 (en) 2018-12-20
AU2007287098C1 (en) 2018-03-15
CN101528308A (zh) 2009-09-09
CY1124221T1 (el) 2022-05-27
KR20180003636A (ko) 2018-01-09
JP2015110577A (ja) 2015-06-18
EP2478907B1 (en) 2021-04-14
HK1131577A1 (en) 2010-01-29
IL197211A0 (en) 2009-12-24
JP2017052791A (ja) 2017-03-16
EP2061561A1 (en) 2009-05-27
RS52956B (sr) 2014-02-28
HRP20210670T1 (hr) 2021-06-11
JP2010501575A (ja) 2010-01-21
PT2061561E (pt) 2013-10-09
IL257681A (en) 2018-04-30
ES2869343T3 (es) 2021-10-25
JP2019059750A (ja) 2019-04-18
NO20091190L (no) 2009-03-20
JP2018065859A (ja) 2018-04-26
AU2022206696A1 (en) 2022-08-11
JP2022185091A (ja) 2022-12-13
PT2478907T (pt) 2021-05-26
RS62034B1 (sr) 2021-07-30
AU2007287098B2 (en) 2013-08-15
NZ597830A (en) 2013-02-22
CA2661422A1 (en) 2008-02-28
NO20200775A1 (no) 2009-03-20
PL2478907T3 (pl) 2021-10-25
WO2008024484A1 (en) 2008-02-28
KR20200125776A (ko) 2020-11-04
HUE054495T2 (hu) 2021-09-28
JP2021038252A (ja) 2021-03-11
EP2478907A3 (en) 2012-08-01
SI2061561T1 (sl) 2013-11-29
LT2478907T (lt) 2021-06-25
JP6740497B2 (ja) 2020-08-12
PL2061561T3 (pl) 2013-12-31
AU2015221447B9 (en) 2017-07-20
CY1115477T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
JP6740497B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US20220265681A1 (en) Abiraterone prodrugs
KR20090060306A (ko) 비타민 ｄ 화합물 및 추가 치료제, 및 그를 함유하는 조성물을 투여하는 것을 포함하는, 암을 치료하는 방법
HK40120426A (zh) 阿比特龙前药
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090324

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120823

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131031

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20140916

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150514

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140916

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20131031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150814

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150514

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101004717

Request date: 20150814

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150914

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101004717; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150814

Effective date: 20170116

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170116

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150814

Decision date: 20170116

Appeal identifier: 2015101004717